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Introduction 
Diabetic ketoacidosis (DKA) continues to be a frequent cause 
of admission to the medical ward. In the developed world, 
the overall mortality rate of adult patients in DKA has been 
reduced to < 1%.1 However, in the South African setting, 
mortality rates remain between 6.8-9%,2,3 positioning DKA 
as an important condition that requires correct recognition 
and management. Furthermore, as the incidence of type 
1 diabetes mellitus appears to be increasing in almost all 
populations worldwide,4 it is likely that more patients will 
present in DKA in the future. In addition, awareness is 
needed of the recently defined entity of ketosis-prone 
diabetes in patients of African origin, who present in DKA, 
but who have the clinical and metabolic features of type 2 
diabetes.5 This review will focus on the treatment of DKA, 
with special emphasis on fluid therapy.
Fluids
Fluid replacement and intravenous insulin administration 
are the primary and most critical initial treatments of 
diabetic ketoacidosis (DKA). While it is accepted that 
fluid resuscitation is a crucial factor, the exact type of 
fluid to be used remains controversial. The fluid lost in 
DKA is predominantly due to osmotic diuresis, caused 
by glycosuria, with minor contributions from vomiting, 
pyrexia and hyperventilation.6  The osmolality of the fluid 
lost is similar to half-normal saline, making it a relatively 
hypotonic fluid. Half the fluid loss in DKA is derived from 
the intracellular compartment, and the other half from the 
extracellular compartment.6 Although fluid is lost from 
all body fluid compartments, patients present clinically 
with hypovolaemia, i.e. depletion of the intravascular 
compartment. In managing a patient who presents in 
DKA, the first priority should be to restore the circulating 
volume and improve tissue perfusion so that insulin may be 
adequately delivered to the sites of action.7
Colloid versus crystalloid solution 
Colloid solutions are more effectively retained in the 
intravascular compartment than crystalloid solutions, and 
are most efficient for rapid resuscitation. However, a recent 
systematic review comparing colloid and crystalloid fluid 
resuscitation across a wide variety of clinical conditions 
(but not including DKA), failed to show a mortality benefit in 
favour of using colloid solutions.8  Crystalloids are preferred 
as they are readily available and inexpensive compared to 
colloid solutions. Unlike colloid solutions, they also don’t 
carry the risk of anaphylaxis. With regard to crystalloid 
solutions, choices include hypotonic solutions such as 
half-normal saline, or isotonic solutions like normal saline 
or Ringer’s lactate. Table I compares the constituents of 
normal saline and Ringer’s lactate. 
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Abstract
Although the mortality of diabetic ketoacidosis (DKA) has decreased substantially in the developed world, high mortality 
rates still prevail in South Africa, thus making this an important condition to recognise early and manage well. This review 
discusses the treatment of DKA, with emphasis on the controversial aspect of initial fluid replacement therapy. Current 
guidelines recommend the use of normal saline. The concern is that normal saline, when used in large volumes, leads to 
the development of a hyperchloraemic metabolic acidosis which is of uncertain clinical significance. This hyperchloraemic 
acidosis is better quantified using Stewart’s model, as opposed to the “traditional” Henderson-Hasselbalch equation. 
Ringer’s lactate is an alternative choice for initial fluid resuscitation, but may exacerbate the high lactate to pyruvate ratio in 
patients in DKA, and may cause hyperkaleamia. Insulin therapy, prevention of electrolyte abnormalities, and the replacement 
of bicarbonate and phosphate, are other important considerations in the management of the patient with DKA. 
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Isotonic versus hypotonic fluid
Since the fluid lost in DKA is hypotonic, should our initial 
choice of fluid replacement be isotonic or hypotonic? 
Hypotonic solutions do not remain intravascular, and for that 
reason are not ideal for the purposes of initial resuscitation. 
However, they do manage to restore total body fluid 
losses with distribution to all three compartments. On the 
other hand, isotonic fluids are more efficient at restoring 
circulatory volume.6 For every litre of infused isotonic saline, 
a quarter normally remains in the circulatory volume.6 
Because isotonic saline remains largely confined to the 
extracellular compartment, it does not provide free water 
to replace intracellular losses. Isotonic fluids are mainly 
distributed to the interstitial space, and if administered in 
excess, may lead to peripheral and pulmonary oedema 
when the interstitial compartment becomes overexpanded.6 
Normal saline versus Ringer’s lactate
Current guidelines from the USA and the UK recommend 
intravenous isotonic fluid replacement in the management 
of DKA. A recent consensus statement from the American 
Diabetes Association9 advocates the use of isotonic 
saline as the initial fluid therapy in the absence of 
cardiac compromise. The Association of British Clinical 
Diabetologists’ guideline10 agrees. In fact, early studies on 
DKA in the 1970s used normal saline,11 and its use continues 
to be advocated in modern textbooks.12
Over the past decade, a number of articles have compared two 
different approaches to interpreting acid-base disorders.13,14 
The “traditional” approach uses the Henderson-Hasselbalch 
equation to describe and classify metabolic acidosis. A 
shortcoming of the traditional approach is that it doesn’t 
allow a distinction between the various possible causes of 
metabolic acidosis. The “modern” approach is Stewart’s 
physical chemical approach:  a model more useful for 
quantifying acid-base disorders. In Stewart’s analysis, there 
are only three independent variables that determine pH: 
• Partial CO2 tension (PCO2).
• Total concentration of weak acid (ATOT). In plasma, 
these consist of albumin and inorganic phosphate. 
• Strong ion difference (SID). The SID describes the 
difference between the concentrations of the strong 
cations (Na+, K+, Mg2+, and Ca2+) and strong anions 
(Cl-, lactate, ketoacids, sulphate and others) in a fluid 
compartment, and may be calculated using the complex 
equation below.
Any change in pH must be because of a change in one or 
more of these independent variables, or in the dependent 
variables, such as hydrogen ion concentration (H+) and 
bicarbonate concentration (HCO3
-). 
Calculation of strong ion gap (SIG)
SIG = [(Na+ + K+ + Ca2+ + Mg2+) – (Cl- + lactate-)] –
(2.46 x 10-8 x PCO2/10 
–pH + [albumin (g/dl)] 
x (0.123 x pH – 0.631) + [PO4- (mmol/l) 
x (pH – 0.469)]
The concern is that administration of large volumes of 
normal saline is associated with the development of a 
hyperchloraemic metabolic acidosis in the majority of 
patients.15 This acidosis may be more accurately described as 
a strong ion acidosis.16 A problem arises when clinicians use 
the base deficit in preference to the anion gap to document 
an improvement in the DKA. The base deficit, although an 
accurate measure of the total metabolic component of an 
acidosis, cannot differentiate between coexistent causes 
like ketosis and hyperchloraemia. Hyperchloraemia, if not 
explicitly recognised as giving rise to acidosis, may mask 
resolution of the ketoacidosis. The unwary clinician may 
erroneously interpret the low bicarbonate as being due to 
ongoing ketosis or hypovolaemia, and this may prompt an 
unnecessary alteration in therapy: either a change in insulin 
dose and/or increased fluid administration. 
This is where Stewart’s theory comes into play. The 
“traditional” Henderson- Hasselbalch model assumes 
that bicarbonate is an independent variable and is not 
influenced by chloride, hence it cannot satisfactorily explain 
the mechanism of the hyperchloraemic acidosis. However, 
Stewart’s strong ion approach provides a mechanistic 
explanation for hyperchloraemic acidosis by using a set of 
equilibria that describes the chemistry of plasma.17
Besides the development of hyperchloraemic acidosis, 
the administration of large volumes of normal saline 
may theoretically cause hyperkalaemia through an 
extracellular shift of K+ ions caused by acute changes 
in blood H+ ion concentration, which occurs secondary 
to the hyperchloraemic acidosis.15 A few small studies 
have suggested that normal saline administration may be 
detrimental to renal function.15 
Table I: Composition of intravenous fluids, based on one-litre bags
Normal saline Ringer’s lactate
Na+  mmol/l 154 130
K+  mmol/l 0 4
Cl-  mmol/l 154 109
Ca2+  mmol/l 0 2.7
HCO3
-  mmol/l 0 0
Lactate mmol/l 0 28
pH 5.0 6.5
Osmolality 308 273
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What about the use of Ringer’s lactate in DKA? There are 
arguments against its use for several reasons. Patients 
in DKA have a high lactate to pyruvate ratio, and the 
28 mmol/l of lactate in Ringer’s lactate could exacerbate 
this.18  Secondly, a litre of Ringer’s lactate contains 4 mmol 
of potassium, which may be life-threatening for a patient 
who is initially hyperkalaemic. Another consideration is the 
cost. One litre of Ringer’s lactate costs R33.72, as opposed 
to R12.77 for a litre of normal saline.19 
Therefore, the question of which fluid replacement is optimal 
in DKA still remains unanswered. No randomised controlled 
trials are currently available to support the superiority of one 
fluid over another. Endocrinologists advocate normal saline, 
whereas critical care specialists argue against it due to the 
likelihood of saline causing a hyperchloraemic acidosis. Yet, 
there is no evidence in the literature that this is clinically 
significant or dangerous to patients. More prospective 
studies in this area are needed.
How much fluid to replace?
The average fluid deficit in an adult presenting in DKA is 
five-to-ten litres,20 or 100 ml/kg. The fluid deficit may be 
calculated using the following formula:
Total body water deficit  
= (0.6 x body weight in kg) x (1-140/serum Na+)21
Corrected Na+ 
= serum Na+ + 1,6 x [(plasma glucose in mmol/l – 5.551)/5.551]
Patients should receive 1-1.5 l of fluid in the first hour,9 and 
thereafter 250-500 ml per hour. The aim is to replace 50% 
of the fluid deficit during the first 12 hours of presentation, 
and the remainder within the next 12-16 hours.22  Since 
hyperglycaemia is corrected faster than ketoacidosis,23 
dextrose-containing fluids should be used once the glucose 
falls to < 14 mmol/l to prevent hypoglycaemia.
Insulin therapy
Insulin remains the main component of DKA management. 
The most common way of administering regular insulin is 
via the intravenous route, either by continuous infusion, or 
by hourly administration of a bolus. A landmark randomised 
controlled trial in patients in DKA demonstrated that insulin 
is effective, irrespective of the route of administration.24 In 
this trial, the group receiving insulin intravenously displayed 
the most rapid fall in plasma glucose and ketones, when 
compared to the groups receiving either subcutaneous or 
intramuscular insulin.24 Subcutaneous insulin was found 
to have a delayed onset of action and prolonged half-life. 
Thus, if carefully titrated, continuous intravenous infusion 
of regular insulin remains the preferred route of therapy 
because of its short half-life and ease of titration.
Current treatment guidelines recommend an initial 
intravenous bolus of regular insulin of 0.1 u/kg, followed 
by an intravenous infusion of 0.1 u/kg/hour.9 A more 
recent randomised controlled trial compared the use of 
this regimen to intravenous infusions of insulin without the 
use of a bolus.25 The findings showed that a bolus dose of 
insulin was unnecessary if a slightly higher insulin infusion 
rate of 0.14 u/kg/hour was used. 
Since the advent of the insulin analogues, studies have 
showed that subcutaneous administration of the insulin 
analogues is an effective alternative to regular insulin 
administered by the intravenous route in patients presenting 
in DKA. Patients with mild-to-moderate DKA were treated 
out of the intensive care unit (ICU) with subcutaneous insulin 
aspart every one or two hours.26 This regimen was found to 
be as safe and effective as an intravenous insulin infusion 
administered in ICU. In this study, there was no mortality, 
no difference in length of hospital stay, and no difference 
in total dose of insulin used. There was approximately 30% 
less cost with the use of insulin analogues in the general 
ward, versus intravenous insulin infusions used in ICU. The 
use of insulin analogues by the subcutaneous bolus route 
may be a safe, effective and cost-saving alternative in 
patients with mild, uncomplicated DKA in the general ward 
setting. However, in our setting, patients are infrequently 
admitted to ICU and receive hourly regular insulin boluses 
in the general ward.     
Potassium replacement
It is important to measure serum potassium levels before 
initiating insulin therapy. Patients in DKA usually present with 
mild-to-moderate hyperkalaemia. In these patients, serum 
potassium levels are an unreliable indicator of total body 
potassium, which is usually depleted. If the initial electrolyte 
panel shows a K+ of < 3.5 mmol/l, potassium replacement 
should commence before initiating insulin therapy to avoid 
the risk of hypokalaemia. Insulin therapy and correction 
of acidosis cause potassium to move into cells, and may 
precipitate severe hypokalaemia with arrhythmias and 
muscle weakness complications. Thereafter, four-hourly 
monitoring of electrolytes should guide the need for further 
potassium replacement as shown in Table II. Potassium 
levels should be maintained within the normal range.
 Table II: Guide to potassium chloride replacement
Serum K+ Replacement
< 3 mmol/l 40 mmol KCl per litre   
3.1-4.0 mmol/l 30 mmol KCl per litre
4.1-5.0 mmol/l 20 mmol KCl per litre
> 5 mmol/l Omit KCl
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Bicarbonate therapy
The use of bicarbonate in the treatment of DKA is 
controversial. A study on both human and animal subjects in 
DKA showed that administration of bicarbonate augments 
ketosis and markedly increases blood acetoacetate and 
B-hydroxybutyrate levels.27 Bicarbonate therapy actually 
led to delayed improvement of blood ketones when 
compared to control subjects, despite more rapid correction 
of acidaemia. 27 A prospective randomised study in 21 
patients showed no beneficial or deleterious effects in those 
receiving bicarbonate therapy for pH between 6.9-7.1.28 
In both prospective and retrospective studies of patients in 
DKA, treated with or without sodium bicarbonate, there were 
no differences in cardiac or neurologic function, incidence 
of hypokalemia or hypoglycemia, or rate of recovery from 
ketoacidosis.28,29,30 Therefore, no clinical benefit has been 
demonstrated by the administration of bicarbonate to treat 
DKA.
There are no prospective randomised studies that have 
used bicarbonate in patients with a pH < 6.9. Despite 
a paucity of data on such patients, in an attempt to err 
on the side of caution, bicarbonate use is advocated in 
these instances. The rationale is that the administration 
of sodium bicarbonate in patients with severe acidaemia 
will increase serum pH, thereby eliminating the potentially 
deleterious effects of acidaemia. Severe acidaemia causes 
a decrease in myocardial contractility, 31 a fall in cardiac 
output and a fall in blood pressure. It also sensitises the 
myocardium to arrhythmias. Acidaemia reduces the 
binding of norepinephrine to its receptors. Protons bind 
to intracellular proteins, as well as extracellular proteins, 
especially albumin and haemoglobin. Thus, acidaemia may 
adversely affect important cell functions such as enzymatic 
reactions, generation of ATP, fatty acid biosynthesis, and 
bone formation and resorption.32 On the positive side, 
a decrease in pH reduces the affinity of haemoglobin for 
oxygen, thereby enhancing delivery of oxygen to tissues: 
also known as the Bohr Effect.
Current recommendations support the use of bicarbonate 
in patients in DKA with an admission pH < 6.9.9 Patients 
should receive 100 mmol of 8.4% sodium bicarbonate 
in 400 ml of water, together with 20 mmol of potassium 
chloride administered at a rate of 200 ml per hour until the 
venous pH is more than 7.0. This infusion may be repeated 
until the pH reaches > 7.0.
It is important to remember that sodium bicarbonate 
therapy is not without potential harm. The sodium load 
may worsen hyperosmolarity and cause hypernatraemia. 
Administration of bicarbonate to humans and animals 
increases blood lactate, as well as ketone bodies.27 
A number of in vitro studies show that alkalinisation hastens 
cell death, i.e. acidosis has been shown to protect cells 
against hypoxic injury in a variety of organs, including the 
heart, lung and liver. 33,34,35 Potassium shifts into cells as pH 
rises, sensitising the heart to arrhythmias. It is important, 
when using bicarbonate, to carefully monitor and replace 
potassium. Serum ionised calcium concentration is reduced 
by sodium bicarbonate infusion.
In a study where normal human volunteers were made 
acidaemic with acetazolamide, and then corrected with 
sodium bicarbonate, the acute correction of the pH caused 
increased haemoglobin affinity for oxygen that worsened 
oxygen delivery to tissues. This effect lasted approximately 
eight hours.36  
In summary, many potentially detrimental effects of 
bicarbonate administration have been identified, but 
whether these observations are all clinically relevant to 
humans in DKA is unknown. Further prospective controlled 
studies are required. 
Phosphate replacement
Patients in DKA typically present with hyperphosphataemia, 
despite whole body deficits in phosphate. However, up to 
90% of patients will become acutely hypophosphataemic 
within six to twelve hours of beginning therapy.37,38 The 
hypophosphatemia, resulting from the treatment of DKA, 
may be attributed to transcellular shifts resulting from a 
number of factors, including fluid resuscitation, correction 
of acidosis, insulin therapy, and use of bicarbonate, which 
lower serum phosphate levels.38,39
Symptomatic hypophosphataemia is usually observed 
when plasma phosphorus falls below 0.32 mmol/l. 
The clinical manifestations of a low serum phosphate 
are diverse, and include altered mineral metabolism, 
disorders of skeletal and cardiac muscle, and respiratory 
depression. Rhabdomyolysis may complicate severe 
hypophosphataemia.40 Another consequence of phosphate 
depletion is respiratory muscle weakness. This may delay 
the recovery of patients receiving mechanical ventilation.41  
Wilson et al showed that the routine use of phosphate 
therapy does not affect the duration of DKA, dose of insulin 
required, rate of fall of glucose, morbidity or mortality.42 
However, a number of studies conducted in settings other 
than DKA show an association between hypophosphataemia 
and increased mortality.43,44  It is unclear as to whether the 
hypophosphataemia contributes to the increased mortality, 
or whether it is just a marker of severity of illness.45
It is generally recommended that patients with severe 
hypophosphataemia (< 0.3 mmol/l) are treated to avoid 
potential detrimental consequences, especially if the 
patients are critically ill, intubated, or are symptomatic. 
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In patients who require it, 20-30 mmol/l of K2PO4 can be 
added to the replacement fluid.9  The infusion rate should not 
exceed 20 mmol per hour of K2PO4.
45 Hypocalcaemia may 
be precipitated by the use of phosphate in the treatment of 
DKA.46
Conclusion
The successful management of a patient in DKA 
requires careful attention, not only with regard to the 
abovementioned points pertaining to correction of 
dehydration, hyperglycaemia and electrolyte imbalances, 
but also to identification of the precipitating event that 
gave rise to the DKA, and management of sepsis. Frequent 
patient monitoring and vigilance for possible complications 
are vital.
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